Mutations in the Epidermal Growth Factor Receptor(EGFR) Gene in Non-Small Cell Lung Carcinoma (NSCLC) and the Relation to Response of Treatment With Erlotinib
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00815971|
Recruitment Status : Unknown
Verified December 2008 by Aarhus University Hospital.
Recruitment status was: Recruiting
First Posted : December 31, 2008
Last Update Posted : December 31, 2008
Recently it has been suggested that specific mutations in the EGFR gene in lung cancer patients is associated with response to a novel drug targeting the EGF system. Recent research also indicates that there is a possible association to the degree of aggressiveness of the disease.
The importance of these mutations is controversial, because the data are based on small studies with highly selected patients.
In this project the investigators want to study the types and frequencies of EGFR mutations in both untreated and treated patients in a systematic manner and relate this to survival.
The thorough registration of patient data in DK enables us to create a strong The investigators expect this knowledge to be of greatest importance for future rational use of drugs targeting the EGF receptors.
|Condition or disease|
|Non-Small Cell Lung Cancer|
- To establish a method for identifying the mutations in the EGFR gene in small clinical samples from lung cancer patients.
- In a retrospective study(n=500) relate survival to the frequency and types of mutations in the EGFR gene in a Danish population of patients with advanced, inoperable non small cell lung cancer (NSCLC) diagnosed prior to the introduction of treatment directed towards EGFR.
- In a prospective study (n=300), to identify the mutations in the EGFR gene in patients treated with erlotinib, a tyrosine kinase inhibitor targeting the EGFR. Presence of mutations will be related to the expression of other parts of the EGF system, to mutations in the gene coding for K-RAS and to treatment response.
|Study Type :||Observational|
|Estimated Enrollment :||300 participants|
|Official Title:||Mutations in the Epidermal Growth Factor Receptor(EGFR) Gene in Non-Small Cell Lung Carcinoma (NSCLC) and the Relation to Response of Treatment With Erlotinib|
|Study Start Date :||May 2008|
|Estimated Primary Completion Date :||May 2011|
|Estimated Study Completion Date :||May 2011|
Patients with non-small cell lung cancer carcinoma treated with erlotinib
- overall survival [ Time Frame: 1 year after the last patient is enrolled ]
- response( according to RECIST) [ Time Frame: 3 month after the last patient is enrolled ]
- quality of live ( measured by EORTC PAL 15) [ Time Frame: 3 month after the last patient is enrolled ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00815971
|Contact: Britta Weber, MDemail@example.com|
|Contact: Peter Meldgaard, PhD MDfirstname.lastname@example.org|
|department of oncology, University Hospital of Aarhus, Nørrebrogade 44||Recruiting|
|8000 Aarhus, Denmark|
|Contact: Britta Weber, MD +4589493333 email@example.com|
|Contact: Peter meldgaard, PhD MD +4589493333 firstname.lastname@example.org|
|Principal Investigator: Peter meldgaard, PhD MD|
|Principal Investigator:||Peter Meldgaard, PhD MD||Aarhus University Hospital|